Development and validation of a nomogram for predicting ICU mortality in patients with acute pancreatitis: dual-center retrospective cohort study

Keywords
acute pancreatitis, nomogram, ICU mortality, MIMIC-IV

Abstract

Introduction

Acute pancreatitis(AP) is a severe inflammatory disease causing abdominal pain and organ failures, potentially leading to necrosis and dysfunction. This study aimed to create a nomogram to predict mortality in intensive care unit(ICU) patients with AP.

Material and methods

We conducted cohort study using the Medical Information Mart for Intensive Care IV(MIMIC-IV) and data from the first people’s hospital of Changde city, selecting variables via univariate logistic regression and constructing a nomogram with multivariate logistic regression. The nomogram's performance was evaluated with the area under the curve (AUC) calculated from the receiver operating curve (ROC), reclassification improvement (NRI) and integrated discrimination improvement (IDI), while clinical utility was assessed with a calibration curve and decision curve analysis (DCA) validated the predictive model's efficacy.

Results

A total of 1100 patients were analyzed, with ICU mortality rates of 7.9% in the training set, 9.2% in the internal validation set, and 13.3% in the external validation set. From the 32 extracted variables, five were ultimately selected: hemoglobin, urea nitrogen, SAPSII score, OASIS score, and myocardial infarction. We subsequently developed and validated a nomogram. The AUC, NRI, and IDI of the nomogram were superior to the traditional SAPSII and OASIS scoring systems. Calibration curves and the Hosmer-Lemeshow test revealed satisfactory alignment between predicted and observed outcomes, while DCA substantiated the clinical utility of the model across a wide range of threshold probabilities.

Conclusions

The nomogram accurately predicted ICU AP patients' mortality and may serve as a valuable tool for clinicians to identify high-risk patients and optimize medical decision-making.

Development and validation of a nomogram for predicting ICU mortality in patients with acute pancreatitis: dual-center retrospective cohort study

Running Head: Nomogram for ICU Mortality Prediction in Acute Pancreatitis:

Abstract

Introduction: Acute pancreatitis(AP) is a severe inflammatory disease causing abdominal pain and organ failures, potentially leading to necrosis and dysfunction. This study aimed to create a nomogram to predict mortality in intensive care unit(ICU) patients with AP.

Material and methods: We conducted cohort study using the Medical Information Mart for Intensive Care IV(MIMIC-IV) and data from the first people's hospital of Changde city, selecting variables via univariate logistic regression and constructing a nomogram with multivariate logistic regression. The nomogram's performance was evaluated with the area under the curve (AUC) calculated from the receiver operating curve (ROC), reclassification improvement (NRI) and integrated discrimination improvement (IDI), while clinical utility was assessed with a calibration curve and decision curve analysis (DCA) validated the predictive model's efficacy.

Results:A total of 1100 patients were analyzed, with ICU mortality rates of 7.9% in the training set, 9.2% in the internal validation set, and 13.3% in the external validation set. From the 32 extracted variables, five were ultimately selected: hemoglobin, urea nitrogen, SAPSII score, OASIS score, and myocardial infarction. We subsequently developed and validated a nomogram. The AUC, NRI, and IDI of the nomogram were superior to the traditional SAPSII and OASIS scoring systems. Calibration curves and the Hosmer-Lemeshow test revealed satisfactory alignment between predicted and observed outcomes, while DCA substantiated the clinical utility of the model across a wide range of threshold probabilities.

Conclusions: The nomogram accurately predicted ICU AP patients' mortality and may serve as a valuable tool for clinicians to identify high-risk patients and optimize medical decision-making.

Keywords: ICU mortality, nomogram, acute pancreatitis, MIMIC-IV.

Introduction

Acute pancreatitis (AP) is one of the most frequent gastrointestinal diseases, with its incidence showing an increasing trend year by year[1-3]. Severe acute pancreatitis (SAP) accounts for approximately 20% of AP cases and is characterized by necrosis of the pancreatic or peripancreatic tissue[4]. In contrast to the more favorable clinical outcomes observed in patients with mild AP, SAP is still associated with a worse prognosis, featuring a substantial mortality rate of 20–40%[5]. This significantly influences the health and quality of life of people around the world[6].

Although the overall mortality rate for AP has decreased owing to enhanced critical care and accurate, timely diagnosis, the severity of mortality and long-term complications persists[7, 8]. Accurate and timely assessment of the condition and prognosis of AP patients holds significant importance for clinicians[9].This facilitates risk stratification of patients and enables the provision of individualized treatment, ultimately contributing to a reduction in mortality risk.

In recent years, the prognosis of AP has been evaluated using various scoring systems, including the Acute Physiology and Chronic Health Evaluation Scoring System II (APACHE II), BISAP scores, as well as biochemical markers such as the glucose-to-lymphocyte ratio and the estimated glomerular filtration rate (eGFR)[10-12]. However, there are no evidence-based practice guidelines available, and the prognostic precision of an individual laboratory biomarker or score system may be susceptible to fluctuations in its accuracy. Currently, there is no efficient and facile prognostic scoring tool to estimate the survival outcomes of AP patients in the Intensive Care Unit (ICU).

Identifying patients with AP at high risk of mortality during their initial admission to the ICU can significantly aid clinicians in achieving timely diagnosis and devising tailored therapeutic strategies. Reviewing the recently published literature, the OASIS score, SAPS II score, elevated blood urea nitrogen (BUN) and malnutrition are significantly associated with an increased risk of mortality related to AP[13-16]. However, few predictive models for ICU mortality in AP incorporate these simple yet effective factors.

Owing to the limitations of current predictive models, developing a predictive model for ICU mortality in AP patients that leverages routine clinical and laboratory data is essential to ensure its ready implementation in clinical practice. It has been verified that nomograms are effective in providing evidence-based and personalized risk estimates, which play a crucial role in optimizing clinical management and assessing patient outcomes. Utilizing demographic characteristics, clinical variables, and laboratory parameter derived from the Medical Information Mart for Intensive Care IV(MIMIC-IV) database and an external validation cohort, our objective was to develop a nomogram model for predicting ICU mortality in patients with AP .

Methods

Source of data

To develop and validate a prediction model, this dual-center retrospective study was conducted involving patients with AP. Internal cohorts were derived from the MIMIC-IV database; eligible patients were randomly allocated in a 7:3 ratio to the training and internal-validation sets, respectively. For external validation, an independent dataset was compiled from the First People's Hospital of Changde City, encompassing patients who met identical inclusion and exclusion criteria and were admitted between February 2020 and February 2023.

The MIMIC-IV database is a dataset that includes comprehensive health-related information from nearly 60,000 patients who were treated in the ICU at the Beth Israel Deaconess Medical Center in the United States. Comprehensive patient data, encompassing demographic characteristics, vital signs, laboratory results, imaging

reports, organ failure assessments, illness severity scores, comorbid conditions, diagnoses, therapeutic interventions, hospital length of stay, and survival outcomes, were documented between 2008 and 2019. We have successfully accomplished an online course offered by the National Institutes of Health (NIH), which has enabled us to gain access to the MIMIC-IV database (certification number: No. 64566867).

Study Population

Utilizing Structured Query Language (SQL) in conjunction with PostgreSQL (version 9.6, University of California, Berkeley), data extraction was performed to retrieve pertinent information linked to each patient's distinct HADM_ID from the MIMIC-IV database. A total of 1345 patients hospitalized in the ICU with AP were identifed from the MIMIC-IV database using the International Classification of Diseases , 9th Edition (ICD - 9) code 5770 and 10th Edition (ICD - 10) code K85. The external validation cohort included patients with AP who were initially admitted to the Hepatobiliary Surgery Department and subsequently transferred to the ICU due to changes in their condition. The exclusion criteria were as follows: (i) Patients with missing data >25% or outcome variable missing; (ii) ICU stay < 24 hours and >90days; (iii)Non-first ICU admission.

Clinical Variables and Definition

During the first day of ICU admission, 32 variables encompassing clinical (age, sex), laboratory(hemoglobin, anion gap, calcium, chloride, creatinine, glucose, potassium, white blood cell [WBC], hematocrit, total bilirubin, platelets, alanine aminotransferase[ALT], aspartate aminotransferase[AST]), comorbidity(myocardial infarct, congestive heart failure[CHF], renal disease, severe liver disease, rheumatic disease, diabetes, chronic obstructive pulmonary disease[COPD], malignant cancer), scoring systems(simplified acute physiology score II[SAPSII], sequential organ failure as severity [SOFA]score, oxford acute severity of illness score[OASIS], systemic inflammatory response syndrome[SIRS], Glasgowcoma scale [GCS], ICU stay, treatments(mechanical ventilation[MV], renal replacement therapy[RRT]), and outcome data were collected. The outcome was mortality during the ICU admission. To address missing data, two methods were employed: 1. variables with > 25%

missing values were excluded; 2. The missing data for the remaining variables was imputed using either the mean or the median.

Risk Nomogram Development and Evaluation

A random selection process was used to assign 70% of the participants from the MIMIC-IV data set to the training set, while the remaining 30% were assigned to the internal validation set. The training set was employed for the construction of a nomogram, whereas the internal validation set was utilized for conducting internal validation. Additionally, an external data set was utilized for testing(external validation). Univariate logistic regression analysis that integrated various characteristics and clinical outcome in the training cohort was applied to variables selection. Employing a multivariable logistic regression algorithm, the risk score was developed based on the selected significant variables($P < 0.05$). These variables were further employed to develop a nomogram for assessing the risk of ICU mortality. The nomogram's performance was evaluated based on the AUC, calibration, and decision and clinical impact curves with 95% confidence intervals (CI).

Statistical Analysis

All statistical analysis were performed using STATA version 15.0 (Stata Corporation, College Station, Texas, USA) and R software version 4.2.1 (The R Foundation for Statistical Computing, Vienna, Austria). Descriptive statistics encompassed both continuous and categorical variables. Continuous variables are expressed as means ± standard deviations (SDs) or medians with interquartile ranges. Categorical variables are presented as frequencies and percentages. For the comparison of continuous variables, Student's t-test or Wilcoxon signed-rank test was employed, whereas categorical variables were analyzed using the chi-square test or Fisher's exact test. A two-tailed p-value less than 0.05 was considered statistically significant.

Results

Patient characteristics

Based on ICD-9 and ICD-10 codes, we identified 6222 patients with AP in the MIMIC-IV database. Among these, 1345 patients were admitted to the ICU. An

additional cohort of 270 AP patients was retrospectively enrolled from the The First People's Hospital of Changde City. After excluding 515 participants who did not meet the inclusion criteria, a total of 1,100 eligible AP patients were finally included. The MIMIC-IV data set was randomly divided into two parts: 70% of the data (n=610) was used for model training, and 30% of the data (n=262) was used for internal validation. The external validation set finally consisted of 228 patients. Figure 1 describes the criteria and procedures for the inclusion and exclusion of the study population. The demographic and clinical data of the included patients are summarized in Table 1 ICU mortality was 7.9% in the training set, 9.2% in the internal validation set, and 13.3% in the external validation set.

Variables Selection

Univariate analysis showed that age, myocardial infarction, severe liver disease, SAPSII score, OASIS score, SOFA score, SIRS score, ICU stay, WBC, urea nitrogen, creatinine, MV, RRT, hemoglobin, anion gap, and GCS score were associated with ICU mortality (Table 2). After the multivariate logistic regression analyses, 5 variables were found to be predictors of ICU mortality (Table 3). These variables were hemoglobin, urea nitrogen, SAPSII score, OASIS score, and myocardial infarction.

Construction and validation of the nomogram

Based on the findings of multivariate logistic regression, we constructed a nomogram to predict mortality in ICU patients with AP. The specific values of hemoglobin, urea nitrogen, SAPSII score, OASIS score, and myocardial infarction can be applied to determine the corresponding points on the nomogram. By consolidating the points derived from each variable, the nomogram calculates the predictive risk of ICU mortality in patients with AP(Figure 2).

Model evaluation and clinical use

In this study, we conducted a comparative analysis of the predictive capabilities of our nomogram and SAPSII score and OASIS score for ICU mortality among patients with AP.

The results indicated that AUC was 0.882 (95% CI: 0.830-0.924) for the training set, 0.920 (95% CI: 0.873-0.951) for the internal validation set, and 0.847 (95% CI: 0.753–0.915) for the external validation set, both of which outperformed the SAPSII and OASIS score. (Figure 3).

NRI values for the nomogram compared to the SAPSII score were 0.154 (95% CI (0.054-0.254), 0.233(95% CI (0.024-0.441) and 0.112(95% CI (0.022- 0.202)in the training, internal validation and external validation sets, respectively; the corresponding IDI values were 0.102 (95% CI 0.063-0.141), P<0.001, 0.051(95% CI 0.017-0.104),P=0.045, and 0.061 (95% CI 0.032-0.090), P<0.001, respectively(Table 4). Analysis comparing the nomogram with OASIS score revealed trends similar to those observed for the SAPSII score (Table 4). These findings suggest that the nomogram has better discriminative ability and outperforms the SAPS-II and OASIS score.

The calibration curve exhibited a satisfactory alignment during internal and external validation (Figure 4). The Hosmer-Lemeshow test demonstrated that our predicted values were close to the observed values for the training set (P = 0.793), for the internal validation set (P = 0.082), and for the external validation set (P = 0.179), which suggests that the model accurately predicted the risk of ICU mortality in AP patients. DCA analysis revealed that the nomogram offers a superior net beneft for predicting ICU mortality when compared to the “treat all or none” strategy, spanning a wide range of threshold probabilities. Furthermore, the nomogram showed a superior standardized net benefit over SAPSII score and OASIS score regarding patient outcomes. (Figure 5)

Discussion

We developed and validated a risk model for the early prediction of ICU mortality for patients with AP based on the MIMIC-IV database and an external validation set. The included variables were typically measured during the crucial first 24 hours after admission. We adhered to the TRIPOD statement's recommendation to use the bootstrapping method for calculating AUCs and calibration curves[17]. The performance of the nomogram was acceptable and robust based on the AUCs, NRI,

and IDI obtained from the training and internal validation sets. Additionally, the calibration tests and DCA results derived from the training and internal validation sets suggests an acceptable overall fit and a good clinical advantage. The positive results were successfully confirmed in the external validation set. This nomogram integrates 5 distinct prognostic factors (hemoglobin, urea nitrogen, SAPSII score, OASIS score, and myocardial infarction) , which are closely related to clinical practice and hold potential clinical reference value. These selected clinical variables are easily accessible and circumvent the necessity for elaborate diagnostic procedures, sophisticated imaging modalities, or invasive maneuvers. It may serve as a potentially useful tool for clinicians and investigators to assess high-risk patients and precisely evaluate the severity of AP.

Our research incorporated two scoring systems, the SAPSII and OASIS scores, to predict ICU mortality, resulting in a more robust and accurate prediction than using either the SAPSII or OASIS score individually. Consistent with our findings, previous studies[18, 19] indicated that the SAPSII and OASIS scores are effective predictors of prognosis for ICU-admitted patients with AP. Additional research has also confirmed that SAPS II and OASIS are reliable tools for predicting outcomes in various patient groups[20, 21]. The SAPS II scoring system assesses various physiological metrics, including heart rate, blood pressure, body temperature, respiratory frequency, and laboratory test outcomes, thereby delivering a comprehensive evaluation of a patient's physiological status and the severity of their illness[22]. In AP, the development of organ dysfunction greatly affects prognosis[23]. The SAPS II score effectively captures these critical changes, offering valuable prognostic information[24]. In contrast, the OASIS score focuses on clinical signs and lab results, making it especially relevant for patients in critical care[25]. A notable characteristic of the OASIS score is its emphasis on evaluating the severity of acute illness, which has demonstrated robust predictive power, especially in scenarios involving infections and multiple organ failure[26].

Moreover, our data also revealed that urea nitrogen (OR: 2.508; 95% CI: 1.182-5.323) is an independent predictor of increased ICU mortality risk in patients

with AP. This result aligns with previous studies that found elevated urea nitrogen levels are a reliable indicator for predicting mortality and severity in AP[27, 28]. Research by Khan, U, et al. showed that patients with AP have higher mortality rates due to myocardial infarction[29]. Additionally, a large sample study also indicates that the development of myocardial infarction is linked to increased morbidity and mortality[30]. Our model also indicated that myocardial infarction (OR: 2.352; 95% CI: 1.015-5.453) is a significant risk factor for ICU mortality, consistent with findings from previous studies.

In our analysis, the majority of factors exhibited a positive correlation with the risk of ICU mortality; conversely, hemoglobin levels demonstrated a negative association (OR: 0.414; 95% CI: 0.175-0.982). Anemia emerged as a crucial and sensitive marker indicative of nutritional inadequacies, with severe cases of anemia correlating with unfavorable outcomes in patients with SAP[31]. Prior research has similarly indicated that reduced hemoglobin levels are linked to an enhanced positive risk of mortality[32]. These findings are consistent with our investigation results. Severe anemia may increase mortality through several pathways: nutritional deficiencies that heighten infection risk, inflammatory processes that hinder erythropoiesis, and bacterial endotoxins that can cause blood loss. Together, these factors reduce oxygen delivery to vital organs, leading to tissue hypoxia and ultimately causing multi-organ dysfunction[33].

Certain limitations of this study necessitate careful consideration. First, This research is a retrospective analysis utilizing data from the MIMIC-IV database, along with a small external validation set for further validation. Additional large-scale, multicenter prospective studies are essential to verify the accuracy of the nomogram. Second, variables such as albumin and fibrinogen with missing values >25% were excluded from the analysis. Third, our study included only ICU-admitted patients with AP (AP), which may result in selection bias. Fourth,owing to inherent limitations of the database, we were unable to perform a detailed analysis of the underlying etiologies of acute pancreatitis or to reliably determine the interval between symptom onset and ICU admission. Finally, without dynamic parameters, we cannot assess the

mortality risk for ICU patients with AP in real-time.

Conclusion

We developed and validated a nomogram to predict mortality in ICU patients with AP using 5 key variables assessed within the first 24 hours of admission. This will help clinicians identify AP patients at high risk of mortality, enabling timely interventions and improving the allocation of medical resources. Further validation of this nomogram with a more diverse dataset is crucial to strengthen its impact on treatment strategies.

Conflict of Interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Acknowledgments

Not applicable.

Author Contributions

YTY and KLZ contributed equally to this work.HJY designed the study, perform statistical analysis and drafted the manuscript. YTY revise the manuscript critically for significant intellectual content. HJY and YTY participated in data collection. XJD extracted the data from the MIMIC-IV database. QZ and KLZ contributed to further analyze and interpret data. All authors has read and consented to the final draft of the article.

Data Availability

The MIMIC-IV data set was publicly shared. Investigators can obtain access by completing an online course known as Protecting Human Research Participants. The preprocessed version of the external validation set used in this study can be obtained by contacting the corresponding author.

Ethical Approval

The authors are responsible for all aspects of this study, ensuring that any issues related to accuracy or integrity of the investigation are thoroughly examined and

satisfactorily resolved. Importantly, the MIMIC IV database has obtained ethical clearance from the Institutional Review Boards (IRBs) at BIDMC and MIT. Additionally, since the database does not include confidential health information, a waiver of the informed consent requirement was granted as part of the IRB's approval procedure.

Consent for publication

Not applicable.

Funding

This research was supported by Hunan Provincial Natural Science Foundation Of China (2025JJ70696),Hunan Science and Technology Innovation Program Grant (2021SK50205) and The science and technology innovation Program of Changde city(2024ZD115,2016KZ09,2016KZ01).

Institutional review board statement

Given the retrospective nature of this study, all informed consent were waived by the ethics community and all analyses were performed in accordance with the Declaration of Helsinki and the ethical guidelines for clinical studies of The First People's Hospital of Changde City.

References:

1. Trikudanathan G, Yazici C, Evans PA, Forsmark CE: **Diagnosis and Management of Acute Pancreatitis.** *Gastroenterology* 2024, **167:**673-688.
2. Cook ME, Knoph CS, Fjelsted CA, Frøkjær JB, Bilgrau AE, Novovic S, Jørgensen MT, Mortensen MB, Nielsen L, Hadi A, et al: **Effects of a peripherally acting μ-opioid receptor antagonist for the prevention of recurrent acute pancreatitis: study protocol for an investigator-initiated, randomized, placebo-controlled, double-blind clinical trial (PAMORA-RAP trial).** *Trials* 2023, **24:**301.
3. Huang S, Ma J, Dai H, Luo L: **A new in-hospital mortality prediction nomogram for intensive care unit patients with acute pancreatitis.** *Arch Med Sci* 2024, **20:**61-70.
4. Qin X, Xiang S, Li W: **Analysis of factors influencing onset and survival of patients with severe acute pancreatitis: A clinical study.** *Immun Inflamm Dis* 2024, **12:**e1267.
5. Leppäniemi A, Tolonen M, Tarasconi A, Segovia-Lohse H, Gamberini E, Kirkpatrick AW, Ball CG, Parry N, Sartelli M, Wolbrink D, et al: **2019 WSES guidelines for the management of severe acute**

pancreatitis. *World J Emerg Surg* 2019, **14:**27.

6. Giorga A, Hughes M, Parker S, Smith A, Young A: **Quality of life after severe acute pancreatitis: systematic review.** *BJS Open* 2023, **7**.

7. Hidalgo NJ, Pando E, Mata R, Fernandes N, Villasante S, Barros M, Herms D, Blanco L, Balsells J, Charco R: **Impact of comorbidities on hospital mortality in patients with acute pancreatitis: a population-based study of 110,021 patients.** *BMC Gastroenterol* 2023, **23:**81.

8. Bender F, König T, Hecker M, Fritzenwanker M, Braun J, Pons-Kühnemann J, Wolff M, Hecker A, Reichert M: **Impact of invasive infections on clinical outcomes in acute pancreatitis: early predictive factors and implications for prophylactic anti-infective therapy.** *Gut Pathog* 2025, **17:**5.

9. Ozturk MO, Aydin S: **Complementary comments on diagnosis, severity and prognosis prediction of acute pancreatitis.** *World J Gastroenterol* 2024, **30:**108-111.

10. Silva-Vaz P, Abrantes AM, Morgado-Nunes S, Castelo-Branco M, Gouveia A, Botelho MF, Tralhão JG: **Evaluation of Prognostic Factors of Severity in Acute Biliary Pancreatitis.** *Int J Mol Sci* 2020, **21**.

11. Zhou H, Mei X, He X, Lan T, Guo S: **Severity stratification and prognostic prediction of patients with acute pancreatitis at early phase: A retrospective study.** *Medicine (Baltimore)* 2019, **98:**e15275.

12. Gong F, Zhou Q, Gui C, Huang S: **Association of estimated glomerular filtration rate and all-cause mortality in acute pancreatitis: a retrospective analysis.** *BMC Anesthesiol* 2023, **23:**121.

13. Ali H, Moond V, Vikash F, Dahiya DS, Gangwani MK, Sohail AH, Chang A, Liu J, Hayat U, Patel P, et al: **Risk score to predict inpatient mortality of acute pancreatitis patients admitted to the intensive care unit.** *Pancreatology* 2024, **24:**1213-1218.

14. Li X, Tian Y, Li S, Wu H, Wang T: **Interpretable prediction of 30-day mortality in patients with acute pancreatitis based on machine learning and SHAP.** *BMC Med Inform Decis Mak* 2024, **24:**328.

15. Silva-Vaz P, Abrantes AM, Castelo-Branco M, Gouveia A, Botelho MF, Tralhão JG: **Multifactorial Scores and Biomarkers of Prognosis of Acute Pancreatitis: Applications to Research and Practice.** *Int J Mol Sci* 2020, **21**.

16. Arvanitakis M, Ockenga J, Bezmarevic M, Gianotti L, Krznarić Ž, Lobo DN, Löser C, Madl C, Meier R, Phillips M, et al: **ESPEN guideline on clinical nutrition in acute and chronic pancreatitis.** *Clin Nutr* 2020, **39:**612-631.

17. Collins GS, Reitsma JB, Altman DG, Moons KG: **Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement.** *BMJ* 2015, **350:**g7594.

18. Huang S, Ma J, Dai H, Luo L: **A new in-hospital mortality prediction nomogram for intensive care unit patients with acute pancreatitis.** *Arch Med Sci* 2024, **20:**61-70.

19. Pan LN, Pan SA, Lei BH, Hong GL, Chen KW: **Development of a Novel Nomogram Incorporating Red Blood Cell Distribution Width-Albumin Ratio for the Prediction of 30-day Mortality in Acute Pancreatitis Patients.** *Emerg Med Int* 2022, **2022:**1573931.

20. Yue S, Li S, Huang X, Liu J, Hou X, Zhao Y, Niu D, Wang Y, Tan W, Wu J: **Machine learning for the prediction of acute kidney injury in patients with sepsis.** *J Transl Med* 2022, **20:**215.

21. El-Manzalawy Y, Abbas M, Hoaglund I, Cerna AU, Morland TB, Haggerty CM, Hall ES, Fornwalt BK: **OASIS +: leveraging machine learning to improve the prognostic accuracy of OASIS severity score for predicting in-hospital mortality.** *BMC Med Inform Decis Mak* 2021, **21:**156.

22. Kahraman F, Yılmaz AS, Ersoy İ, Demir M, Orhan H: **Predictive outcomes of APACHE II and expanded SAPS II mortality scoring systems in coronary care unit.** *Int J Cardiol* 2023, **371:**427-431.
23. Choi MH, Kim D, Choi EJ, Jung YJ, Choi YJ, Cho JH, Jeong SH: **Mortality prediction of patients in intensive care units using machine learning algorithms based on electronic health records.** *Sci Rep* 2022, **12:**7180.
24. Colussi G, Perrotta G, Pillinini P, Dibenedetto AG, Da PA, Catena C, Sechi LA: **Prognostic scores and early management of septic patients in the emergency department of a secondary hospital: results of a retrospective study.** *BMC Emerg Med* 2021, **21:**152.
25. Sarkar R, Martin C, Mattie H, Gichoya JW, Stone DJ, Celi LA: **Performance of intensive care unit severity scoring systems across different ethnicities in the USA: a retrospective observational study.** *Lancet Digit Health* 2021, **3:**e241-e249.
26. Fan S, Ma J: **The value of five scoring systems in predicting the prognosis of patients with sepsis-associated acute respiratory failure.** *Sci Rep* 2024, **14:**4760.
27. Metri A, Bush N, Singh VK: **Predicting the severity of acute pancreatitis: Current approaches and future directions.** *Surg Open Sci* 2024, **19:**109-117.
28. Pando E, Alberti P, Mata R, Gomez MJ, Vidal L, Cirera A, Dopazo C, Blanco L, Gomez C, Caralt M, et al: **Early Changes in Blood Urea Nitrogen (BUN) Can Predict Mortality in Acute Pancreatitis: Comparative Study between BISAP Score, APACHE-II, and Other Laboratory Markers-A Prospective Observational Study.** *Can J Gastroenterol Hepatol* 2021, **2021:**6643595.
29. Khan U, Petrechko O, Sagheer S, Majeed H, Zaidi SH, Wasty N, Sheikh AB: **Acute Pancreatitis and Myocardial Infarction: A Narrative Review.** *Cardiology* 2023, **148:**1-11.
30. Khanna T, Patel J, Singh I, Kalra S, Dhiman M, Kohli I, Chaudhry H, Dukovic D, Sohal A, Yang J: **The Impact of Type 2 Myocardial Infarction in Acute Pancreatitis: Analysis of 1.1 Million Hospitalizations and Review of the Literature.** *Cureus* 2023, **15:**e44113.
31. Cai YL, Wang SQ, Zhong HJ, He XX: **The effect of anemia on the severity and prognosis of patients with acute pancreatitis: A single-center retrospective study.** *Medicine (Baltimore)* 2022, **101:**e32501.
32. Xiong J, Tan H, Mao S, Ma L, Ma K: **Association Between Hemoglobin-to-Red Blood Cell Distribution Width Ratio and 30-Day Mortality in Patients with Acute Pancreatitis: Data from MIMIC-III and MIMIC-IV.** *Turk J Gastroenterol* 2024, **35:**651-664.
33. Sankaran VG, Weiss MJ: **Anemia: progress in molecular mechanisms and therapies.** *Nat Med* 2015, **21:**221-230.

Development and validation of a nomogram for predicting ICU mortality in patients with acute pancreatitis: dual-center retrospective cohort study

Multicenter cohort study

MIMIC-IV Database
Training Cohort (n = 610)
Internal Validation (n = 262)

The First People's Hospital of Changde City
External Validation (n = 228)

Total Patients: 1,100
ICU Mortality: 7.9%-13.3%

The nomogram used for predicting the ICU mortality in intensive care patients with acute pancreatitis.



Model validation & clinical utility

Discriminative Performance:
Training AUC:0.882;
Internal Validation AUC:0.920
External Validation AUC:0.847

Clinical Application:
1.High-risk patient identification
2.Treatment decision support
3. Superior to existing scores



Haojie Yang， et al.2025. Archives of Medical Science

Table 1 Baseline demographic and clinical characteristics of patients with acute pancreatitis.

Variables	Training cohort(n = 610)	Internal validation cohort(n = 262)	External validation cohort(n = 228)
Gender			
Female	262 (43.0%)	108 (41.2%)	98 (43.0%)
Male	348 (57.0%)	154 (58.8%)	130 (57.0%)
Age			
⩽60	310 (50.8%)	151 (57.6%)	120 (52.6%)
>60	300 (49.2%)	111 (42.4%)	108 (47.4%)
Myocardial infarction			
no	544 (89.2%)	238 (90.8%)	205 (89.9%)
yes	66 (10.8%)	24 (9.2%)	23 (10.1%)
CHF			
no	487 (79.8%)	215 (82.1%)	178 (78.1%)
yes	123 (20.2%)	47 (17.9%)	50 (21.9%)
Renal disease			
no	493 (80.8%)	220 (84.0%)	171 (75.0%)
yes	117 (19.2%)	42 (16.0%)	57 (25.0%)
Severe liver disease			
no	553 (90.7%)	231 (88.2%)	194 (85.1%)
yes	57 (9.3%)	31 (11.8%)	34 (14.9%)
Rheumatic disease			
no	586 (96.07%)	252 (96.18%)	217(95.1%)
yes	24 (3.93%)	10 (3.82%)	11(4.9%)
Diabetes			
no	439 (71.97%)	186 (70.99%)	153 (67.1%)
yes	171 (28.03%)	76 (29.01%)	75 (32.9%)
COPD			
no	478 (78.36%)	208 (79.39%)	186 (81.8%)
yes	132 (21.64%)	54 (20.61%)	42 (18.2%)
Malignant cancer			
no	566 (92.79%)	236 (90.08%)	212 (93.0%)
yes	44 (7.21%)	26 (9.92%)	16 (7.0%)
GCS			
3-8	119 (19.5%)	41 (15.6%)	50 (22.0%)
9 – 12	101 (16.6%)	38 (14.5%)	40 (17.5%)
13 – 15	390 (63.9%)	183 (69.8%)	138 (60.5%)
SOFA			
⩽10.5	475 (77.9%)	211 (80.5%)	106 (46.5%)
>10.5	135 (22.1%)	51 (19.5%)	122 (53.5%)
SAPSII			
⩽48.5	473 (77.5%)	205 (78.2%)	184 (80.7%)

＞48.5	137 (22.5%)	57 (21.8%)	44 (19.3%)
OASIS			
≤44.5	501 (82.1%)	208 (79.4%)	183 (80.3%)
≥44.5	109 (17.9%)	54 (20.6%)	45 (19.7%)
SIRS	3.0[2.0;4.0]	3.0 [3.0;4.0]	3.0 [2.0;4.0]
Urea nitrogen (mg/dL)			
≤26	368 (60.3%)	174 (66.4%)	110 (48.3%)
＞26	242 (39.7%)	88 (33.6%)	118 (51.7%)
MV			
No	391 (64.1%)	168 (64.1%)	134 (58.8%)
Yes	219 (35.9%)	94 (35.9%)	94 (41.2%)
RRT			
No	568 (93.1%)	242 (92.4%)	208 (91.2%)
Yes	42 (6.9%)	20 (7.6%)	20 (8.8%)
Hemoglobin(g/dL)			
≤8.6	78 (12.8%)	43 (16.4%)	68 (29.8%)
＞8.6	532 (87.2%)	219 (83.6%)	160 (70.2%)
Anion gap (mmol/L)			
≤16	338 (55.4%)	140 (53.4%)	108 (47.4%)
>16	272 (44.6%)	122 (46.6%)	120 (52.6%)
ALT (U/L)			
≤40	238 (39.0%)	100 (38.2%)	91 (39.9%)
>40	372 (61.0%)	162 (61.8%)	137 (60.1%)
AST (U/L)			
≤35	146 (23.9%)	64 (24.4%)	52 (22.8%)
>35	464 (76.1%)	198 (75.6%)	176 (77.2%)
Calcium(mg/dL)	8.1 [7.4;8.6]	8.1 [7.4;8.7]	8.0 [7.3;8.6]
Chloride(mmol/L)	104.0 [98.0;108.0]	103.5 [99.0;108.0]	103.0 [99.0;107.0]
Creatinine(mg/dL)	1.1 [0.8;2.0]	1.0 [0.7;1.8]	1.5 [0.8;2.7]
Glucose(mg/dL)	129.0 [104.0;183.8]	126.5 [105.0;179.8]	133.0 [107.0;190.5]
Potassium(mmol/L)	4.1 [3.7;4.6]	4.1 [3.7;4.6]	4.2 [3.8;4.6]
WBC(K/uL)	12.9 [9.0;18.4]	12.1 [8.5;17.2]	12.4 [8.6;19.0]
Hematocrit(g/dL)	35.0 [25.3;38.1]	34.9 [27.2;39.5]	32.6 [26.2;39.1]
Total bilirubin(mg/dL)	1.0 [0.6;2.5]	1.0 [0.5;2.6]	1.6 [0.6;3.6]
Platelets(K/uL)	196.0 [138.0;278.0]	208.5 [146.5;298.8]	187.0 [126.8;272.5]
ICU stay(days)	2.80 [1.34;6.30]	2.55 [1.33;7.22]	3.1 [1.6;8.6]
ICU Mortality (%)			
no	562(92.1%)	238(90.8%)	198 (86.7%)
yes	48(7.9%)	24(9.2%)	30 (13.3%)

ICU, intensive care unit; SAPSII, simplified acute physiology score II; OASIS, Oxford acute severity of illnessscore; SIRS, systemic inflammatory response syndrome; SOFA, Sequential

Organ Failure Assessment; MV, mechanical ventilation; RRT, renal replacement therapy; WBC, white blood cell; ALT, aspartate aminotransferase; AST, alanine aminotransferase; COPD, Chronic pulmonary disease; CHF, Congestive heart failure; GCS, Glasgow Coma Scale.

Table 2 The univariate logistic regression analysis of risk factors associated with ICU mortality in patients with acute pancreatitis.

Variables	Subgroup	Univariate Analysis		
		OR	95% CI	P-value
age	⩽60	1		0.006
	>60	2.328	1.273-4.260	
Myocardial infarction	No	1		0.002
	Yes	3.010	1.489-6.085	
Severe liver disease	No	1		0.010
	Yes	2.586	1.257-5.318	
Urea nitrogen(mg/dL)	⩽26	1		<0.001
	>26	5.787	3.014-11.113	
Hemoglobin (g/dL)	⩽8.6	1		0.029
	>8.6	0.463	0.232-0.925	
Anion gap (mmol/L)	⩽16	1		0.002
	>16	2.671	1.447-4.931	
MV	No	1		<0.001
	Yes	3.412	1.901-6.124	
RRT	No	1		0.001
	Yes	3.665	1.702-7.894	
GCS	⩾13 and ⩽15	1		<0.001
	⩾9 and ⩽12	2.432	1.069-5.536	
	⩾3 and ⩽8	5.399	2.824-10.321	
SAPSII	⩽48.5	1		<0.001
	>48.5	19.550	9.679-39.489	
OASIS	⩽44.5	1		<0.001
	>44.5	16.239	8.416-31.334	
SOFA	⩽10.5	1		<0.001
	>10.5	14.765	7.585-28.738	
SIRS		1.606	1.106-2.330	0.013
ICU stay(days)		3.540	1.980-6.330	<0.001
WBC (K/uL)		1.038	1.007-1.069	0.015
Creatinine(mg/dL)		1.178	1.037-1.324	0.007

ICU, intensive care unit; SAPSII, simplified acute physiology score II; OASIS, Oxford acute severity of illnessscore; SIRS, systemic inflammatory response syndrome; SOFA, Sequential Organ Failure Assessment; MV, mechanical ventilation; RRT, renal replacement therapy; WBC, white blood cell; GCS, Glasgow Coma Scale; OR, Odds Ratio; CI, Confidence Interval.

Table 3 Selected variables by multivariate logistic regression analysis.

Variable	Subgroup	Multivariate analysis		
		OR	95%CI	P-value
Hemoglobin (g/dL)	⩽8.6	1		0.045
	>8.6	0.414	0.175-0.982	
Urea nitrogen (mg/dL)	⩽26	1		0.017
	>26	2.508	1.182-5.323	
SAPSII	⩽48.5	1		<0.001
	>48.5	5.440	2.267-13.052	
OASIS	⩽44.5	1		<0.001
	>44.5	5.346	2.330-12.267	
Myocardial infarction	No	1		0.046
	Yes	2.352	1.015-5.453	

SAPSII, simplified acute physiology score II; OASIS, Oxford acute severity of illnessscore; OR, Odds Ratio; CI, Confidence Interval.

Table 4 Predictive performances and validation of the nomogram.

Predictive model	**AUC**	**P**	**NRI**	**P**	**IDI**	**P**
Training set						
Nomogram	0.882(0.830-0.924)					
SAPSII	0.766 (0.699-0.835)	<0.001	0.154(0.054-0.254)	<0.001	0.102(0.063-0.141)	<0.001
OASIS	0.806 (0.736-0.872)	0.001	0.154(0.054-0.254)	0.003	0.066(0.031-0.102)	<0.001
Internal validation set						
Nomogram	0.920 (0.873-0.951)					
SAPSII	0.820 (0.758-0.872)	0.036	0.233(0.024-0.441)	0.029	0.051(0.017-0.104)	0.045
OASIS	0.798 (0.688-0.893)	<0.001	0.160(0.010-0.311)	0.037	0.112(0.056-0.168)	<0.001
External validation set						
Nomogram	0.847(0.753-0.915)					
SAPSII	0.817 (0.719-0.899)	0.002	0.112(0.022-0.202)	0.015	0.061(0.032-0.090)	<0.001
OASIS	0.800 (0.687-0.888)	0.008	0.291(0.257-0.425)	<0.001	0.050(0.012-0.112)	0.043

AUC: Area Under the Curve; NRI: Net Reclassification Improvement; IDI: Integrated Discrimination Improvement; SAPSII, simplified acute physiology score II; OASIS, Oxford acute severity of illnessscore.



Figure 1: Flow chart of the study population.



Figure 2: The nomogram used for predicting the ICU mortality in intensive care patients with acute pancreatitis.



Figure 3:The AUC of the nomogram and comparisons of risk prediction performance (the nomogram, SAPS II, and OASIS). (A)The AUC of the nomogram in training, internal validation, and external validation sets, respectively. (B) Comparisons of risk prediction performance in training dataset. (C) Comparisons of risk prediction performance in internal validation set. (D)Comparisons of risk prediction performance in external validation set.)



Figure 4:The calibration curve of the nomogram for predicting ICU mortality. (A) The calibration curve in training set; (B) The calibration curve in internal validation set□(C) The calibration curve in external validation set.



Figure 5: Decision curve analysis (DCA)of the nomogram to predict ICU mortality. (A) Decision curve in training set; (B) Decision curve in internal validation set□(C) Decision curve in external validation set.